–Data results shared across facial injectables, body contouring and skincare portfolio highlights Allergan Aesthetics' continued commitment to advancing aesthetic medicine
–Analyses of 15 years of post-marketing surveillance data demonstrate the global reported rate of delayed-onset nodules associated with dermal fillers on the Vycross technology platform is low (<0.016%).
–Results from 3 clinical studies showcasing a customizable platform with patent-pending LTN Complex, to address the appearance of facial hyperpigmentation in a wide range of demographic populations
–Dr. DiAnne Davis to discuss the new Forces of Beauty^® Report from the DREAM (Driving Racial Equity in Aesthetic Medicine) Initiative^® and at Diversity, Equity and Inclusion (DEI) reception

NORTH CHICAGO, Ill., Oct. 4, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its third-quarter 2022 financial results on Friday, October 28, 2022, before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. CT. It will be accessible through AbbVie's Investor Relations website investors.abbvie.com. An archived edition of the session will be available later that day.

NORTH CHICAGO, Ill., Sept. 29, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) today revealed the spectrum of new data from studies of risankizumab (SKYRIZI^®) in Crohn's disease and upadacitinib (RINVOQ^®) in ulcerative colitis and Crohn's disease that will be presented as live presentations and e-Posters at the United European Gastroenterology (UEG) Week 2022, October 8-11 in Vienna and online. In total, AbbVie is presenting 17 abstracts across a broad range of studies in inflammatory bowel disease (IBD).

IRVINE, Calif. and PHOENIX, Sept. 22, 2022 /PRNewswire/ -- Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), and skinbetter science^® announce a new report from their DREAM (Driving Racial Equity in Aesthetic Medicine) Initiative^®, along with a long-term partnership with Shutterstock Studios. The report, titled Forces of Beauty^®, provides a new understanding of what inclusive and representative beauty looks like today by shedding light on how narrowly defined Eurocentric ideals continue to impact women of color. By surveying over 4,000 women aged 21-65, from multiple geographic locations and backgrounds, the report explores what defines beauty, how beauty impacts women's lives, and the interplay between beauty and race. Some key insights include:

^-  CHMP positive opinion is based on results from three Phase 3 studies: two for induction and one for maintenance^1,2
-  Crohn's disease is a chronic, systemic disease that manifests as inflammation within the gastrointestinal tract, causing persistent diarrhea, abdominal pain and can require urgent medical care^3,4
-  If approved, risankizumab will be the first specific IL-23 inhibitor for the treatment of Crohn's disease in the European Union (EU)
^-  The European Commission decision is expected in the fourth quarter of 2022. This anticipated approval would mark the third indication for risankizumab in the EU

--Results will be presented from the Phase 3 M15-736 trial, a randomized, double-blind, double-dummy, active-controlled study, evaluating the continuous subcutaneous infusion of ABBV-951 (foslevodopa/foscarbidopa) in people with advanced Parkinson's disease
--Data will also be presented on real-world efficacy of BOTOX^® (onabotulinumtoxinA) for the treatment of spasticity and BOTOX^® for the treatment of cervical dystonia
--Research highlights AbbVie's continued commitment to advancing the management of movement disorders

NORTH CHICAGO, Ill., Sept. 14, 2022 /PRNewswire/ -- AbbVie today announced the start of its two-week public voting period for the 2022 Thriving Undergraduate and Graduate Scholarships. Following this voting period, scholarships totaling $25,000 each will be awarded to two commendable students living with cystic fibrosis (CF), an inherited chronic disease that affects the lungs and digestive system.

IRVINE, Calif., Sept. 13, 2022 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), is unveiling the 25 real patients – of all forms, genders, ethnicities and backgrounds – who were selected to participate in the latest iteration of the BOTOX^® Cosmetic 'See Yourself' campaign. After receiving nearly 20,000 submissions to its first-ever open casting call, BOTOX^® Cosmetic, the #1 selling product of its kind¹, is creating a content series that captures inspiring and intimate accounts of people speaking candidly about how they see themselves and their motivation for being treated with BOTOX^® Cosmetic.

- Analyses included 100-week efficacy and safety data from the four-year, open-label extension period of KEEPsAKE 1 and 2 evaluating SKYRIZI in patients with active psoriatic arthritis¹

NORTH CHICAGO, Ill., Sept. 9, 2022 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of $1.41 per share.